Biomarkers in Blood Samples From Patients With Refractory Non-Small Cell Lung Cancer Previously Treated With Sorafenib Tosylate
Recruitment status was: Not yet recruiting
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is studying biomarkers in blood samples from patients with refractory non-small cell lung cancer previously treated with sorafenib tosylate.
Genetic: DNA analysis
Genetic: mutation analysis
Other: laboratory biomarker analysis
|Official Title:||BRAF, KRAS and EGFR Mutation Detection in Non-Small Cell Lung Cancer Patients Treated With Sorafenib Monotherapy|
- Mutation rate of sorafenib tosylate-target gene BRAF, and its upstream proteins KRAS and EGFR [ Designated as safety issue: No ]
- Association between BRAF, KRAS, and EGFR mutation status and clinical benefits (stable disease or partial response) [ Designated as safety issue: No ]
|Study Start Date:||June 2010|
|Estimated Primary Completion Date:||July 2010 (Final data collection date for primary outcome measure)|
- To determine the mutation rates of BRAF, KRAS, and EGFR in patients with non-small cell lung cancer treated with sorafenib tosylate on protocol ECOG-2501.
- To determine the association between BRAF, KRAS, or EGFR mutation status and clinical benefits in patients treated with this regimen.
OUTLINE: This is a multicenter study.
DNA is isolated from archived plasma samples and analyzed for BRAF, KRAS, and EGFR mutations.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01124669
|Principal Investigator:||Christine Chung, MD||Vanderbilt-Ingram Cancer Center|